David Soergel - 01 Jun 2026 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Reporting relationship: Chief Medical Officer
Issuer ticker: MDGL
Reported as of: 01 Jun 2026
Net transaction value: -$516,561
SEC form: 4
Accepted by SEC: 01 Jun 2026, 19:49:09 UTC
Prior SEC filing: 18 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Mardi Dier, as Attorney-in-Fact

Key filing fact

David Soergel filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 01 Jun 2026.

Key facts

This page summarizes David Soergel's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Jun 2026, 19:49.

Change

Previous filing in this sequence was filed on 18 May 2026.
Current net transaction value: -$516,561.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001591475 Primary reporting owner

Soergel David

Relationship: Chief Medical Officer
Address: C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 200, WEST CONSHOHOCKEN
Signature: /s/ Mardi Dier, as Attorney-in-Fact
Signature date: 01 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDGL transaction

Common Stock

Sale

Transaction value: $516,561
Shares: -1,042
Change %: -9.4%
Price: $495.74
Shares after: 10,033
Date: 01 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026.